|
||||||||||||||||||||||||||||||||
 |
The Speakers
Discuss the commercial, clinical and regulatory viability of developing a biosimilar with experts such as:
| Philippe Stas | Chief Operating Officer | ALGONOMICS |
| Alan Colley | Senior Regulatory Affairs Manager | AMGEN |
| Raja Velagapudi | Director, Pharmacokinetics and Bioequivalence | BARR LABORATORIES |
| Louis Christian Clauss | Director of New Product Development | BAXTER INTERNATIONAL |
| Cornelia Ulm | Head of Regulatory Affairs and Quality Assurance | BIOPARTNERS |
| Helmut Brunar | VP Research & Business Development, Biosimilars | KWIZDA PHARMA |
| Andrea Rappagliosi | VP Health Policy & Market Access | MERCK SERONO |
| Henning Blume | CEO | SOCRATEC R&D |
| Jay Madan | Vice President, Business Development Biopharmaceuticals |
RELIANCE LIFE SCIENCES |
| Harald Sitte | Institute of Pharmacology | MEDICAL UNIVERSITY VIENNA |
| Asterios Tsiftsoglou | Professor, Pharmocognosy-Pharmacology | ARISTOTLE UNIVERSITY OF THESSALONIKI |
| Ivan Cohen-Tanugi | Vice President, Global BioGenerics, Portfolio, Strategy & Marketing |
TEVA EUROPE |
| Murali Tummuru | CEO | VIRCHOW BIOTECH |
| Hemanth Nandigala | Executive Director, Commerce | VIRCHOW BIOTECH |
